` CAN (Cann Group Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

CAN
vs
S
S&P/ASX 300

Over the past 12 months, CAN has underperformed S&P/ASX 300, delivering a return of -76% compared to the S&P/ASX 300's +7% growth.

Stocks Performance
CAN vs S&P/ASX 300

Loading
CAN
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CAN vs S&P/ASX 300

Loading
CAN
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
CAN vs S&P/ASX 300

Loading
CAN
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Cann Group Ltd vs Peers

S&P/ASX 300
CAN
LLY
JNJ
ROG
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Cann Group Ltd
Glance View

Market Cap
13.8m AUD
Industry
Pharmaceuticals

Cann Group Ltd. operates research and development and cultivation facilities to grow medicinal cannabis. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-05-04. The firm has established research and cultivation facilities in Melbourne and is developing a cultivation facility near Mildura, Victoria. The company focuses on developing and supplying cannabis, cannabis resin and medicinal cannabis products into the Australian market. The firm has a cannabis research license and cannabis cultivation license. The cannabis cultivation license allows the Company to produce Australian grown material that can be prescribed for patient use. The company focuses on plant genetics, breeding, cultivation, extraction, analysis and production techniques to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions.

CAN Intrinsic Value
0.027 AUD
Undervaluation 67%
Intrinsic Value
Price
Back to Top